Logo

Sanofi Collaborated with IGM Biosciences to Develop & Commercialize IgM Antibody Agonists Against Oncology, Immunology and Inflammation Targets

Share this

Sanofi Collaborated with IGM Biosciences to Develop & Commercialize IgM Antibody Agonists Against Oncology, Immunology and Inflammation Targets

Shots:

  • IGM to receive $150M up front & ~$6B in development, regulatory & commercial milestones along with royalties. For 3 oncology targets, both companies will share the profits equally while Sanofi will lead the development & commercialization activities
  • IGM will lead the R&D activities & assume related costs through the US FDA & EMA’s approval of 1st BLA in return for ~$940M in development & regulatory milestones for each oncology target program
  • Upon the completion of P-I trial for each immunology/inflammation target program, Sanofi will lead the future development & related costs in exchange for ~$1,065M in development & regulatory & commercial milestones/ immunology/inflammation target

Ref: Globe Newswire | Image: Sanofi

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions